



(51) International Patent Classification:

C07D 401/04 (2006.01) *A61K 31/4035* (2006.01)
A61K 31/403 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2021/051648

(22) International Filing Date:

23 September 2021 (23.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/082,365 23 September 2020 (23.09.2020) US

(71) Applicant: **ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.** [US/US]; 262 Danny Thomas Place, Memphis, Tennessee 38105 (US).

(72) Inventors: **FISHER, Marcus**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **KERAMATNIA, Fatemeh**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **MCGOWAN, Kevin**;

c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **MIN, Jaeki**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **NISHIGUCHI, Gisele A.**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **PRICE, Jeanine**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **RANKOVIC, Zoran**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **SOURAV, Das**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **MULLIGHAN, Charles G.**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US). **CHANG, Yunchao**; c/o ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., 262 Danny Thomas Place, Memphis, Tennessee 38105 (US).

(54) Title: SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN




FIG. 1

(57) Abstract: In one aspect, the disclosure relates to substituted N-(2-(2,6-dioxopiperidinyl-3-yl)-1,3-dioxoisindolin-5-yl)arylsulfonamide analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction and/or a GSPT1 dysfunction. In various further aspects, the disclosed compounds can selectively modulate the degradation of GSPT1 protein, i.e., the disclosed compounds can act as GSPT1 degraders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

[Continued on next page]

(74) **Agent: TIMMER, Richard T.;** THE SEARS GROUP, LLC DBA INNOVATORS LEGAL, 1266 West Paces Ferry Road NW, #609, Atlanta, Georgia 30327 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*